ArticleDiscover oncology2025
Mapping thirty years of tumour-microenvironment-driven drug resistance in breast cancer: a global bibliometric analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immunotherapy 3.0: Breakthroughs Steering the Next Generation of Cancer Control.Cancer reports (Hoboken, N.J.) · 2026Review
- Unravelling the nexus of non-coding RNAs in cancer stemness and therapeutic drug resistance.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study charted how investigations of tumour-microenvironment (TME) dynamics have shaped global thinking on drug resistance in breast cancer over the past three decades.
methodsWeb of Science Core Collection records (1995–2024) were harvested on 15 May 2025 with a three-block Boolean string integrating disease, microenvironmental, and resistance terms. After duplicate removal, document-type filtering, language restriction, and natural-language adjudication, 1 303 original articles and reviews remained. Bibliometrix (R 4.3.2) generated annual output, citation kinetics, and growth rates; VOSviewer (fractional counting, resolution = 1.0) mapped co-authorship, co-citation, and keyword networks.
resultsPublication volume expanded at a compound annual rate of 18.7%, progressing through formative (1995–2004), consolidation (2005–2012), and expansionary (2013–2024) epochs. Keyword drift traced a pivot from endocrine-centric lexicons (“tamoxifen”, “estrogen receptor”) to TME-immune discourse (“extracellular vesicles”, “tumour-associated macrophages”, “nanoparticles”); “microenvironment”, “hypoxia”, and “multidrug resistance” emerged as high-betweenness semantic bridges. The United States–China dyad accounted for 56.1% of output and anchored 24.4% of internationally co-authored papers, funnelling methodological innovation into an increasingly multipolar network, here defined as a collaboration graph containing at least four countries that each contribute ≥ 5% of total node-level betweenness centrality. Institutional overlays revealed late-decade ascendancy of East-Asian medical universities, while legacy North-American and European centres maintained brokerage dominance.
conclusionBibliometric cartography documents a decisive ecological re-framing of breast-cancer drug-resistance research, with immune-stromal crosstalk supplanting receptor-centric models. Cross-border, multi-omics consortia that fuse East-Asian clinical scale with Western technological depth appear best poised to convert TME insights into resistance-reversing interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.